In recent study, 9 percent of participants taking placebo developed COVID-19 versus 2.9 percent of people taking ensitrelvir
THURSDAY, March 20, 2025 (HealthDay News) — For household contacts of individuals with COVID-19, taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well tolerated, according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 9 to 12 in San Francisco.
Akimasa Fukushi, M.D., of Shionogi & Co., Ltd, in Osaka, Japan, and colleagues randomly assigned household contacts (HHC) of index patients (IP) with COVID-19 to receive either ensitrelvir (1,030 participants; day 1: 375 mg; day 2 to 5: 125 mg) or placebo (1,011 participants) within 72 hours of symptom onset in the IP.
The researchers found that the overall proportion of HHC developing confirmed COVID-19 was significantly lower in the ensitrelvir group (2.9 percent) versus the placebo group (9.0 percent; risk ratio [RR], 0.33) for HHC with central laboratory-confirmed SARS-CoV-2 negativity by reverse transcription polymerase chain reaction (RT-PCR). For HHC regardless of central laboratory RT-PCR results at baseline, similar results were seen (RR, 0.43). Across both groups, the proportions developing treatment-emergent adverse events (TEAEs; 15.1 percent for ensitrelvir and 15.5 percent for placebo) or serious TEAEs (0.2 versus 0.2 percent) were similar, as were the TEAEs seen in >1.5 percent of patients in either group: headache (2.9 versus 2.5 percent), diarrhea (1.8 versus 1.3 percent), and influenza (1.1 versus 1.6 percent). No COVID-19-related hospitalizations or fatalities were seen.
“In addition to vaccination, postexposure prophylaxis with timely use of an oral antiviral would be a valuable way to help prevent COVID-19 illness in people who have been exposed, especially people at high risk for severe disease,” presenting author Frederick G. Hayden, M.D., from the University of Virginia in Charlottesville, said in a statement.
The study was funded by Shionogi & Co., Ltd, the manufacturer of ensitrelvir.
Suboptimal Adherence to Brain Health Recommendations Common in Early Alzheimer Disease 
Report Highlights Substance Use in Young Adults in U.S. in 2025 
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome 
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD 
Considerable Gaps Identified in LDL Cholesterol Control 
87.5 Million U.S. Adults Now Eligible for Statins Under New Guidelines 
Differences in Cardiovascular Risk Factor Prevalence ID"d for South Asian Adults 
